Meeting
2015 ASCO Annual Meeting
Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.
Authors
Jessica Jiyeong Lin
Brigham and Women's Hosp, Brighton, MA
Jessica Jiyeong Lin , Stephanie Cardarella , Christine A. Lydon , Suzanne Eleanor Dahlberg , David Michael Jackman , Pasi A. Janne , Bruce E. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8071)
DOI
10.1200/jco.2015.33.15_suppl.8071
Abstract #
8071
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
First Author: Rahul Shenolikar
Poster
2019 ASCO Annual Meeting
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
First Author: Caicun Zhou
Poster
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
First Author: Julien Mazieres
Poster
2018 ASCO Annual Meeting
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
First Author: Pasi A. Janne